As of 2025-07-09, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 10.3x | 8.2x |
| Forward P/E multiples | 11.2x - 17.7x | 14.9x |
| Fair Price | (21.29) - (19.90) | (21.80) |
| Upside | -683.2% - -645.3% | -697.4% |
| Date | EV/EBITDA |